Nomogram to detect clinically significant prostate cancer for lesions in th - Evidencio
Nomogram to detect clinically significant prostate cancer for lesions in the peripheral zone in patients with PSA between 4-20 ng/mL

Purpose: To develop and externally validate nomograms integrating quantitative apparent diffusion coefficient (ADC) sequence, Prostate Imaging Reporting and Data System (PI-RADS) derived from biparametric MRI (bp-MRI), and clinical indicators to detect prostate cancer (PCa) and clinically significant prostate cancer (csPCa) in patients with prostate specific antigen (PSA) between 4-20 ng/mL.

Materials and methods: Nomograms were developed using data from a cohort of suspected prostate cancer patients with elevated PSA of 4–20 ng/mL who underwent prostate MRI and biopsy at our institution between January 1, 2018, and August 31, 2023 (n = 440). The outcomes were the presence of csPCa and PCa. Nomograms were constructed separately for lesions located in the peripheral and transitional zones. Significant variables identified through univariate logistic analysis and LASSO regression analysis were used to construct four separate nomograms. These nomograms were subsequently validated and evaluated using an external independent cohort of patients obtained from the Prostate Imaging: Cancer AI (PI-CAI) database (n = 313).

Results: A total of 131 (29.8%) and 106 (33.9%) patients had csPCa in the training and external validation cohorts, respectively. Age, PI-RADS, ADC, and PSA density (PSAD) were independent predictors in the prediction model for csPCa in the peripheral zone (PZ), showing an area under the curve (AUC) of 0.934 (95% CI, 0.906-0.962). For csPCa in the transitional zone (TZ), PI-RADS, ADC, and PSAD were independent predictors, with an AUC of 0.903 (95% CI, 0.824-0.983). Additionally, PI-RADS and ADC were independent predictors for PCa in PZ, with an AUC of 0.882 (95% CI, 0.840-0.925), while PI-RADS and PSAD were independent predictors in TZ, with an AUC of 0.764 (95% CI, 0.683-0.844). All four nomograms demonstrated good discrimination with high AUCs in the external validation cohort. Calibration curves indicated good agreement, and decision curve analyses (DCAs) confirmed the clinical benefits of the nomograms.

Conclusions: ADC proved to be the strongest predictor of csPCa in both PZ and TZ, and for PCa specifically in PZ. We developed nomograms integrating ADC, bp-MRI-derived PI-RADS, age and PSAD to detect csPCa and PCa in patients with PSA of 4–20 ng/mL.

Autori della ricerca: Kunlin Wu
Versione: 2.0
  • Pubblico
  • Urologia
  • {{ modelType }}
  • Algoritmo
  • Dettagli
  • Convalidare
  • Salvare l'input
  • Ingresso di carico

  • {{ toolbarErrorMessage }}

Display
Unità

{{ section.title }}

{{ section.description }}

Calcolare il risultato

Impostare altri parametri per eseguire il calcolo

Risk of csPCa in PZ is .

{{ resultSubheader }}
{{ $t('download_result_availability') }}
{{ chart.title }}
Intervallo di risultati {{ additionalResult.min }} a {{ additionalResult.max }}

Informazioni condizionali

Il tuo testo è stato modificato. Aggiorna il risultato. Aggiornare
{{ file.classification }}
PRO
Nota
Le note sono visibili solo nel download dei risultati e non vengono salvate da Evidencio.

Questo algoritmo viene fornito a scopo educativo, formativo e informativo. Non deve essere utilizzato a supporto di decisioni mediche o per fornire servizi medici o diagnostici. Leggete il nostro sito completo disclaimer.

Algoritmi sottostanti Parte di
Commenti
Commento
Inserisci un commento
I commenti sono visibili a chiunque

Feedback del algoritmo

Ancora nessun feedback 1 Commento {{ model.comments.length }} Commenti
Su {{ comment.created_at }} {{ comment.user.username }} un autore non più registrato ha scritto:
{{ comment.content }}
logo

Effettuare l'accesso per abilitare le funzionalità di stampa di Evidencio

Per utilizzare le funzioni di stampa di Evidencio, è necessario aver effettuato il login.
Se non si dispone di un account comunitario Evidencio, è possibile creare un account personale gratuito all'indirizzo:

https://www.evidencio.com/registration

Risultati stampati - Esempi {{ new Date().toLocaleString() }}

Vantaggi del conto comunitario Evidencio

With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.

Esclusione di responsabilità: i calcoli da soli non dovrebbero mai dettare la cura del paziente e non sostituiscono il giudizio professionale.
Termini e condizioni Informativa sulla privacy Disclaimer Contatto Rifiuta i cookie
Evidencio v3.40 © 2015 - 2026 Evidencio. Tutti i diritti riservati